Skip to main content
. 2018 Jan 16;68(667):e114–e122. doi: 10.3399/bjgp18X694589

Table 1.

Baseline characteristics of all screened patients with newly diagnosed hypertension

Variable All patients with available data, n/n PA negative/PA positive PA negative PA positive P-value
Demographics
  Sex (male), n (%) 334/9 173 (51.8) 4 (44.4) 0.744
  Age, years, mean (SD) 334/9 53.4 (11.2) 54.3 (9.2) 0.763
  BMI, kg/m2, n (%) 213/9 0.498
    ≤25 47 (22.1) 1 (11.1)
    >25–≤30 96 (45.1) 6 (66.7)
    >30 70 (32.9) 2 (22.2)
  Smoking status, n (%) 163/9 0.404
    Current 36 (22.1) 2 (22.2)
    Former 55 (33.7) 1 (11.1)
    Never 72 (44.2) 6 (66.7)

Blood pressure, mean (SD)
  Systolic BP, mmHg 332/9 163.8 (13.4) 158.6 (10.2) 0.174
  Diastolic BP, mmHg 329/9 96.3 (9.9) 95.3 (9.1) 0.747
  ABPM, mmHg 47/2 154.2 (15.7) 166.5 (9.2) 0.282
  ABPMday, mmHg 42/1 159.3 (15.6) 161.0 (−)
  Home BP, mmHg 2/0 160.0 (0)
  Heart rate, beats/minute 192/7 75.2 (12.6) 68.6 (12.8) 0.224

Biochemical parameters
  Serum potassium, mmol/l, mean (SD) 332/9 4.43 (0.33) 4.11 (0.26) 0.006
  Serum sodium, mmol/l, mean (SD) 332/9 141.7 (2.0) 141.7 (2.6) 0.951
  Serum creatinine, µmol/l, mean (SD) 332/9 78.8 (14.6) 75.8 (13.1) 0.510
  Plasma aldosterone, pmol/l, mean (SD) 334/9 360.9 (220.5) 668.4 (118.1) <0.001
  Renin, pmol/l, median (IQR) 334/9 0.78 (0.58 to 1.33) 0.48 (0.34 to 0.68) 0.003
  ARR, pmol/mU, mean (SD) 334/9 29.8 (22.8) 105.3 (48.6) 0.002
  Serum glucose, mmol/l, mean (SD) 301/9 5.4 (1.0) 5.4 (0.5) 0.750

Cardiovascular morbidity, n (%)
  OSAS 334/9 5 (1.5) 0 1.000
  Atrial fibrillation 334/9 2 (0.6) 0 1.000
  Stroke 334/9 2 (0.6) 0 1.000
  Myocardial infarction 334/9 2 (0.6) 0 1.000

ABPM = ambulatory blood pressure monitoring. ARR = aldosterone-to-renin ratio. BMI = body mass index. Home BP = home systolic blood pressure. IQR = interquartile range. OSAS = obstructive sleep apnoea syndrome. PA = primary aldosteronism. SD = standard deviation.